These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 23903369

  • 1. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.
    Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
    [Abstract] [Full Text] [Related]

  • 2. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 3. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [Abstract] [Full Text] [Related]

  • 4. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):803-811. PubMed ID: 26912543
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.
    Am J Kidney Dis; 2011 May 06; 57(5):692-9. PubMed ID: 21333426
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators.
    N Engl J Med; 2017 Nov 16; 377(20):1930-1942. PubMed ID: 29105594
    [Abstract] [Full Text] [Related]

  • 7. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators.
    Clin J Am Soc Nephrol; 2011 Oct 16; 6(10):2499-507. PubMed ID: 21903984
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.
    Clin J Am Soc Nephrol; 2018 Aug 07; 13(8):1153-1161. PubMed ID: 30026287
    [Abstract] [Full Text] [Related]

  • 11. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP, Meaney CJ.
    Pharmacotherapy; 2014 Jun 07; 34(6):605-16. PubMed ID: 24706579
    [Abstract] [Full Text] [Related]

  • 12. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators.
    Am J Nephrol; 2017 Jun 07; 45(3):257-266. PubMed ID: 28166521
    [Abstract] [Full Text] [Related]

  • 13. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.
    J Am Soc Nephrol; 2017 May 07; 28(5):1592-1602. PubMed ID: 27920153
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].
    Lacquaniti A.
    G Ital Nefrol; 2013 May 07; 30(1):. PubMed ID: 25083527
    [No Abstract] [Full Text] [Related]

  • 16. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1749-56. PubMed ID: 26231191
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
    Casteleijn NF, Messchendorp AL, Bae KT, Higashihara E, Kappert P, Torres V, Meijer E, Leliveld AM.
    Clin Exp Nephrol; 2017 Jun 07; 21(3):375-382. PubMed ID: 27339446
    [Abstract] [Full Text] [Related]

  • 19. Role of vasopressin antagonists.
    Torres VE.
    Clin J Am Soc Nephrol; 2008 Jul 07; 3(4):1212-8. PubMed ID: 18434616
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.